Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms.
OBJECTIVE
The aim of our work is to study the possible role of clinical variables, neuropsychological performance, and the 5HTTLPR, rs25531, and val108/58Met COMT polymorphisms on the prediction of depression remission after 12 weeks' treatment with fluoxetine. These variables have been studied as potential predictors of depression remission, but they present poor prognostic sensitivity and specificity by themselves.


METHODS
Seventy-two depressed patients were genotyped according to the aforementioned polymorphisms and were clinically and neuropsychologically assessed before a 12-week fluxetine treatment.


RESULTS
Only the La allele of rs25531 polymorphism and the GG and AA forms of the val 108/158 Met polymorphism predict major depressive disorder remission after 12 weeks' treatment with fluoxetine. None of the clinical and neuropsychological variables studied predicted remission.


CONCLUSIONS
Our results suggest that clinical and neuropsychological variables can initially predict early response to fluoxetine and mask the predictive role of genetic variables; but in remission, where clinical and neuropsychological symptoms associated with depression tend to disappear thanks to the treatment administered, the polymorphisms studied are the only variables in our model capable of predicting remission. However, placebo effects that are difficult to control require cautious interpretation of the results.
Facultad de Psicología, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Mexico. ferre@umich.mx
Esteve
E
Gudayol-Ferré
Ixchel
I
Herrera-Guzmán
Beatriz
B
Camarena
Carlos
C
Cortés-Penagos
Jorge E
JE
Herrera-Abarca
Patricia
P
Martínez-Medina
Juan
J
Asbun-Bojalil
Yuridia
Y
Lira-Islas
Celia
C
Reyes-Ponce
Joan
J
Guàrdia-Olmos
D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002394:Catechol O-Methyltransferase / Q000235:genetics* / Q000378:metabolism; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004351:Drug Resistance; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D056726:Genetic Association Studies; D006801:Humans; D008297:Male; D008800:Mexico; D008875:Middle Aged; D009483:Neuropsychological Tests; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D012074:Remission Induction; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics* / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
D000928:Antidepressive Agents; D002394:Catechol O-Methyltransferase; D005473:Fluoxetine; D050486:Serotonin Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors; C493230:SLC6A4 protein, human